Publications by authors named "Mike Ingham"

Claim this Profile
A
Assessment of racial and ethnic inequities in copay card utilization and enrollment in copay adjustment programs.
Mike Ingham, Kay Sadik, Xiaohui Zhao, Ji Song, A Mark Fendrick

J Manag Care Spec Pharm· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in Type II diabetes patients.
Craig I Coleman, Shivani Pandya, Li Wang, Onur Baser, Jennifer Cai, Mike Ingham

J Comp Eff Res· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.
Carol H Wysham, Patrick Lefebvre, Dominic Pilon, Marie-Hélène Lafeuille, Bruno Emond, Mike Ingham

J Diabetes Complications· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality goal attainment and maintenance in patients with type II diabetes mellitus initiated on canagliflozin or a glucagon-like peptide-1 receptor agonist in an actual practice setting.
Carol H Wysham, Dominic Pilon, Mike Ingham, Marie-Hélène Lafeuille, Bruno Emond

Curr Med Res Opin· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Carol H Wysham, Dominic Pilon, Mike Ingham, Marie-Hélène Lafeuille, Bruno Emond

Endocr Pract· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality measure and weight loss assessment in patients with type 2 diabetes mellitus treated with canagliflozin or dipeptidyl peptidase-4 inhibitors.
Carol H Wysham, Patrick Lefebvre, Dominic Pilon, Mike Ingham, Marie-Hélène Lafeuille

BMC Endocr Disord· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs.
Jennifer H Lofland, Phaedra T Johnson, Mike P Ingham, Sarah C Rosemas, John C White

Patient Prefer Adherence· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Retrospective Study on the Impact of Adherence in Achieving Glycemic Goals in Type 2 Diabetes Mellitus Patients Receiving Canagliflozin.
Erin K Buysman, Amy Anderson, Shaffeeulah Bacchus, Mike Ingham

Adv Ther· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effectiveness of step therapy policies for specialty pharmaceuticals in immune disorders.
Chris M Kozma, Mike Ingham, Andy Paris, Lorie Ellis

J Med Econ· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The cost-effectiveness of atypicals in the UK.
Bart Heeg, Erik Buskens, Marc Botteman, Sue Caleo, Mike Ingham

Value Health· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis